Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Validation of a New Methodology for Mapping the Human Blood-Retinal Barrier Function
This study is currently recruiting participants.
Verified by Association for Innovation and Biomedical Research on Light and Image, September 2008
Sponsored by: Association for Innovation and Biomedical Research on Light and Image
Information provided by: Association for Innovation and Biomedical Research on Light and Image
ClinicalTrials.gov Identifier: NCT00759044
  Purpose

To validate a new methodology, named Retinal Leakage Analysis (RLA), for mapping the human Blood-Retinal Barrier (BRB) function, in the clinical practice.


Condition
Age-Related Maculopathy
Diabetic Macular Edema

Genetics Home Reference related topics: X-linked juvenile retinoschisis
MedlinePlus related topics: Edema
U.S. FDA Resources
Study Type: Observational
Study Design: Cohort, Prospective
Official Title: Validation of a New Methodology for Mapping the Human Blood-Retinal Barrier Function

Further study details as provided by Association for Innovation and Biomedical Research on Light and Image:

Primary Outcome Measures:
  • Blood-Retinal Barrier (BRB) function measured by Retinal Leakage Analysis (RLA). [ Time Frame: -- ] [ Designated as safety issue: No ]

Biospecimen Retention:   None Retained

Biospecimen Description:

Estimated Enrollment: 90
Study Start Date: March 2008
Groups/Cohorts
AMD
Patients diagnosed with AMD
DME
Patients diagnosed with DME

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Patients with AMD or DME followed regularly by their ophthalmologist at the AIBILI Clinical Trial Center will be asked to perform additional optical examinations as a continuation of the routine fluorescein angiographies (FA).

Criteria

Inclusion Criteria:

  • Patients diagnosed with AMD, or
  • Patients diagnosed with DME
  • Age over 18 years
  • Inform consent

Exclusion Criteria:

  • Cataract or other eye disease that may interfere with fundus examinations
  • Glaucoma
  • Dilatation of the pupil < 5 mm
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00759044

Contacts
Contact: AIBILI SA aibili@aibili.pt
Contact: AIBILI CNTM seccntm@aibili.pt

Locations
Portugal
AIBILI Clinical Trial Center Recruiting
Coimbra, Portugal, 3000-548
Principal Investigator: José G Cunha-Vaz, Prof.            
Sub-Investigator: Rui C Bernardes, PhD            
Sponsors and Collaborators
Association for Innovation and Biomedical Research on Light and Image
Investigators
Principal Investigator: José G Cunha-Vaz, Prof. Association for Innovation and Biomedical Research on Light and Image
  More Information

Publications:
Responsible Party: AIBILI ( Prof. José G Cunha-Vaz )
Study ID Numbers: CNTM023A
Study First Received: September 24, 2008
Last Updated: September 24, 2008
ClinicalTrials.gov Identifier: NCT00759044  
Health Authority: Portugal: AIBILI-Comissão de Ética para a Saúde

Study placed in the following topic categories:
Macular Edema
Eye Diseases
Retinal Degeneration
Macular Degeneration
Edema
Retinal Diseases
Retinal degeneration

ClinicalTrials.gov processed this record on January 16, 2009